Literature DB >> 10390248

Altered pharmacokinetics of ceftazidime in critically ill patients.

C M Gómez1, J J Cordingly, M G Palazzo.   

Abstract

Many critically ill patients have increased extracellular fluid which might affect ceftazidime pharmacokinetics. We investigated the pharmacokinetics of ceftazidime in 15 adult intensive care patients receiving 2 g of ceftazidime intravenously three times a day. The ceftazidime mean (standard deviation) apparent volume of distribution and terminal-phase half-life were 56.91 (25.93) liters and 4.75 (1.85) h, respectively, significantly greater than values reported previously for healthy controls (P < 0.001). The mean ceftazidime clearance and area under the curve at steady state were not significantly different from those previously reported for controls. We conclude that ceftazidime pharmacokinetics in critically ill patients were altered by an increased volume of drug distribution and elevated elimination half-life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390248      PMCID: PMC89369          DOI: 10.1128/AAC.43.7.1798

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Intermittent bolus dosing of ceftazidime in critically ill patients.

Authors:  R J Young; J Lipman; T Gin; C D Gomersall; G M Joynt; T E Oh
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

2.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 4.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

5.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 6.  Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics.

Authors:  D J Waxman; J L Strominger
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

7.  Simulation of human plasma levels of beta-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters.

Authors:  K Hatano; Y Wakai; Y Watanabe; Y Mine
Journal:  Chemotherapy       Date:  1994 Jan-Feb       Impact factor: 2.544

8.  Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

Authors:  H Hanberger; L E Nilsson; M Nilsson; R Maller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

Review 9.  The pathogenesis of sepsis.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

10.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  19 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 3.  Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.441

Review 4.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

5.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.

Authors:  Bernard Georges; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

6.  Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.

Authors:  Joël Cousson; Thierry Floch; Thomas Guillard; Véronique Vernet; Pascal Raclot; Aurore Wolak-Thierry; Damien Jolly
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

7.  Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.

Authors:  Ronilda D'Cunha; Thanh Bach; Beth Ann Young; Peizhi Li; Demet Nalbant; Jun Zhang; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 8.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 9.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.